Call 866-997-4948 (Us-Canada Toll Free) Tel: +1-518-618-1030 with your industry research requirements or email the details on email@example.com
Opportunity Analyzer Allergic Conjunctivitis Opportunity Analysis and Forecasts to 2018
The allergic conjunctivitis market has remained relatively static over the last few years, due to a limited number of new products. It is currently dominated by dual-acting products and corticosteroid therapies, which form the core treatment options for both acute and chronic allergic conjunctivitis sufferers. Although these therapies provide effective treatment regimens, there are opportunities for the development of alternative treatment choices, improvements in efficacy, safety and compliance. By 2018, there will be three new entrants to the allergic conjunctivitis market. These new products will help drive market growth and offset the impending patent expiries of the majority of the remaining brands (Lotemax, Patanol and Lastacaft) during the forecast period, which will permit the entry of inexpensive generics. Despite these advancements in the treatment landscape, the allergic conjunctivitis market is not expected to experience a noticeable change in terms of growth.
To Browse a Full Report with Toc: http://www.researchmoz.us/opportunityanalyzer-allergic-conjunctivitis-opportunity-analysis-and-forecasts-to-2018-report.html
- The main driver of the expansion of the allergic conjunctivitis market will be the introduction of three new therapies across the 6 major markets.
- The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for allergic conjunctivitis, which will result in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period.
- The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe,...